6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | -$30M | 0.0% | -2346.0% | -$19M | $0 | $19M |
| 2024 | $1M | -$30M | 0.0% | -5186.2% | -$36M | $25M | $4M |
| 2023 | $0 | -$34M | — | — | -$52M | $30M | $6M |
| 2022 | $0 | -$31M | — | — | -$48M | $30M | $27M |
| 2021 | $3M | -$8M | 0.0% | -1899.1% | -$33M | $0 | $117M |
| 2020 | $462000 | — | 0.0% | -3581.0% | -$16M | $4M | $73M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2M | -$7M | 0.0% | -488.2% | -$7M | — | $10M |
| Dec '25 | $1M | -$10M | 0.0% | -584.2% | $294000 | $0 | $19M |
| Sep '25 | $0 | -$5M | — | — | -$5M | $14M | $4M |
| Jun '25 | $0 | -$7M | — | — | -$6M | $18M | $10M |
| Mar '25 | $172000 | -$7M | 0.0% | -6984.3% | -$8M | $21M | $10M |
| Dec '24 | $1M | -$9M | 0.0% | -1455.1% | -$9M | $25M | $4M |
| Sep '24 | $0 | -$7M | — | — | -$9M | $29M | $4M |
| Jun '24 | $0 | -$7M | — | — | -$9M | $30M | $5M |
| Mar '24 | $0 | -$7M | — | — | -$9M | $30M | $7M |
| Dec '23 | — | -$7M | — | — | -$13M | $30M | $6M |
| Sep '23 | — | -$9M | — | — | -$15M | $30M | $5M |
| Jun '23 | — | -$9M | — | — | -$13M | $30M | $8M |
| Mar '23 | — | -$8M | — | — | -$12M | $30M | $19M |
| Dec '22 | $0 | -$9M | — | — | -$15M | $30M | $27M |
| Sep '22 | $0 | -$8M | — | — | -$13M | $15M | $27M |
| Jun '22 | $0 | -$8M | — | — | -$11M | — | $97M |
| Mar '22 | — | -$6M | — | — | -$10M | — | $108M |
| Dec '21 | $0 | -$5M | — | — | -$12M | $0 | $117M |
| Sep '21 | $0 | -$3M | — | — | -$11M | $0 | $130M |
| Jun '21 | $2M | -$5M | 0.0% | -268.1% | -$6M | $0 | $69M |
How the market has priced RANI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Rani Therapeutics Holdings, Inc.'s revenue has grown 28.7% per year. These are computed facts, not advice.
As of FY2025, Rani Therapeutics Holdings, Inc. reported $0 of total debt against $19M of cash; operating income covered interest expense -13.3×.
In FY2025, gross margin was —, operating margin -2346.0%, and net margin -1817.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.